GlassScriptPhysician profile
Robin Williams Adami
NPI 1982046124
$5,939.45
in general payments reported to CMS, 2019-2025
31 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,304 · 2022: $1,128 · 2023: $1,326 · 2024: $1,156 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,405 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.32 |
| Education | $102.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $919.35 | 2021-2025 | Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $711.92 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Janssen Pharmaceuticals, INC | $568.05 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $556.19 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $465.39 | 2021-2025 | Verquvo, Capvaxive, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $354.65 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $323.67 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.70 | 2022-2025 | Jardiance |
| United Therapeutics Corporation | $309.92 | 2022-2024 | Tyvaso, Orenitram |
| Pfizer INC. | $207.51 | 2021-2025 | |
| Amgen INC. | $200.96 | 2021-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $173.89 | 2021-2022 | |
| Cvrx, INC. | $122.08 | 2023 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $103.00 | 2021-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $82.95 | 2021-2023 | Arcalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $78.03 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.82 | 2021-2023 | Lifevest |
| Abbott Laboratories | $67.90 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $42.21 | 2024 | Arcalyst |
| Philips North America LLC | $38.12 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $35.45 | 2021 | |
| Medtronic, INC. | $31.41 | 2021 | |
| G Medical Diagnostic Services, INC. | $24.78 | 2022 | |
| Astellas Pharma US INC | $19.19 | 2021 | |
| Boston Scientific Corporation | $17.89 | 2022 | |
| Lilly USA, LLC | $17.76 | 2025 | Zepbound |
| Bridgebio Pharma, INC. | $17.62 | 2025 | Attruby |
| Scpharmaceuticals INC. | $15.53 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.50 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.28 | 2021 | |
| Esperion Therapeutics, INC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Adami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.